Table 4. Analysis of EVs Derived from Lung Cancer Cells.

CEVs × 10–9 [particles·mL–1]
sample	NTA	SPR			QCMD
		anti-CD9	anti-CD63	anti-CD81	anti-CD9	anti-CD63	anti-CD81
EVs Isolated from Lung Cancer Cells (A549 Cell Line)
sample 1	3.67 ± 0.31	2.63 ± 1.05	2.97 ± 0.80	4.15 ± 1.05	4.66 ± 0.87	3.42 ± 1.03	3.45 ± 0.70
sample 2	3.23 ± 0.46	2.45 ± 0.65	3.11 ± 0.26	2.76 ± 0.62	2.89 ± 1.12	3.68 ± 0.98	4.05 ± 1.50
sample 3	3.82 ± 0.15	3.21 ± 0.75	3.45 ± 0.68	3.22 ± 0.57	3.56 ± 1.13	4.21 ± 1.12	4.30 ± 1.24
sample 4	1.80 ± 0.12	2.03 ± 0.77	2.35 ± 0.65	1.98 ± 0.35	2.07 ± 0.90	2.35 ± 1.50	2.20 ± 0.80
EVs Isolated from Lung Cancer Cells Derived from Lung Patients (Primary Cell Lines)
987	2.60 ± 0.15	1.83 ± 0.86	2.48 ± 0.70	2.06 ± 0.78	2.26 ± 0.80	2.98 ± 1.10	3.14 ± 0.60
3486	4.22 ± 0.18	3.49 ± 1.12	4.95 ± 0.86	4.05 ± 0.87	3.98 ± 1.32	4.80 ± 1.23	3.80 ± 1.20
3994	4.78 ± 0.15	5.21 ± 0.89	4.56 ± 0.35	4.98 ± 0.46	5.40 ± 1.41	4.50 ± 1.23	5.10 ± 1.87
9303	24.3 ± 0.05	17.2 ± 2.62	26.2 ± 2.45	22.6 ± 3.75	27.9 ± 3.20	25.3 ± 2.30	27.5 ± 3.30